List of Appendices
Appendix 1. Aspirin Professional Labeling / Proposed Labeling
Appendix 2. Aspirin Worldwide Cardiovascular Indications
Appendix 3. Coronary Disease Risk Prediction Score Sheets for Women and Men Based on Total Cholesterol Level
Appendix 4. British Doctors’ trial (BDT): Peto, R.; Gray, R.; Collins, R.; Wheatley, K.; Hennekens, C.; Jamrozik, K.; Warlow, C.; Hafner, B.; Thompson, E.; Norton, S.; Gilliland, J.; Doll, R. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.
Appendix 5. Hypertension Optimal Treatment trial (HOT): Hansson, L.; Zanchetti, A.; Carruthers, S.G.; Dahlöf, B.; Elmfeldt, D.; Julius, S.; Ménard, J.; Rahn, K.H.; Wedel, H.; Westerling, S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
Appendix 6. Physicians’ Health Study (PHS): Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N.Engl.J.Med. 1989; 321: 129-135.
Appendix 7. Primary Prevention Project (PPP): Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
Appendix 8. Thrombosis Prevention Trial (TPT): Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
Appendix 9. Eidelman, R.S.; Hebert, P.R.; Weisman, S.M.; Hennekens, C.H. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease. Arch Intern Med. 2003; 163: 2006-10.
Appendix 10. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.